6-Methylquinoline is a heterocyclic organic compound with the molecular formula C10H9N. It is a colorless liquid with a pungent odor. It is a known intermediate in the synthesis of various pharmaceuticals, including antimalarials, antibacterials, and anti-inflammatory agents. The compound has also been studied for its potential applications in organic electronics, due to its ability to form conducting polymers. 6-Methylquinoline has been synthesized through various methods, including the Skraup synthesis, the Doebner-Miller reaction, and the Friedländer synthesis. Its biological activity has been investigated for its potential anti-inflammatory, anticancer, and antimicrobial properties. Furthermore, 6-Methylquinoline has also been explored as a fluorescent probe for metal ions. It is studied for its potential applications in various fields due to its unique chemical structure and biological properties. '
| ID Source | ID |
|---|---|
| PubMed CID | 7059 |
| CHEMBL ID | 1412508 |
| CHEBI ID | 140761 |
| SCHEMBL ID | 130884 |
| MeSH ID | M0217231 |
| Synonym |
|---|
| AC-5219 |
| EN300-28823 |
| BB 0260887 |
| 91-62-3 |
| nsc-4152 |
| nsc4152 |
| 6-methylquinoline , |
| quinoline, 6-methyl- |
| tolliquinoline, p- |
| quinoline, 6-methyl- (8ci,9ci) |
| p-toluquinoline |
| nsc 4152 |
| inchi=1/c10h9n/c1-8-4-5-10-9(7-8)3-2-6-11-10/h2-7h,1h |
| NCGC00091226-01 |
| ai3-08869 |
| brn 0110336 |
| einecs 202-084-6 |
| 6-methylquinoline, >=98%, fg |
| 6-methylquinoline, 98% |
| ccris 407 |
| fema no. 2744 |
| nistc91623 |
| smr001307317 |
| MLS002303009 |
| M0416 |
| NCGC00091226-02 |
| NCGC00091226-03 |
| AC-907/25014269 |
| 6-methyl-quinoline |
| HMS3039C14 |
| dtxcid50887 |
| dtxsid3020887 , |
| NCGC00253998-01 |
| cas-91-62-3 |
| tox21_300320 |
| tox21_202379 |
| NCGC00259928-01 |
| AKOS005207038 |
| k14453i13n , |
| 5-20-07-00400 (beilstein handbook reference) |
| unii-k14453i13n |
| FT-0621247 |
| SCHEMBL130884 |
| 6-methyl quinoline |
| 6-methylquinoline [fhfi] |
| methylquinoline, 6- |
| CHEMBL1412508 |
| J-518932 |
| 6-methylquinoline, analytical standard |
| mfcd00006804 |
| p-tolliquinoline |
| fema 2744 |
| CHEBI:140761 |
| AS-11473 |
| AMY13382 |
| Q27281809 |
| Z277960616 |
| Class | Description |
|---|---|
| quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 48.5084 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 43.2331 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 54.4273 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 16.1019 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 68.5896 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 0.7079 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.5396 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||